October 28, 2023 

Times posted in Eastern Time Zone

Session 1
9:00 AM – Introduction and overview of the day
9:06 AM – What to know about using electronic health record data
9:12 AM – Ins and outs of specific EHR databases
9:18 AM – What to know about using insurance claims data
9:24 AM – Ins and outs of specific claims databases
9:30 AM – Specialty databases
9:36 AM – Panel discussion

Session 2: Neovascular Age-Related Macular Degeneration
9:46 AM – Key Findings from the Voyager study
9:52 AM – Injection frequency and VA outcomes in exudative AMD
9:58 AM – Real-world management of nAMD in the US – Vestrum analysis
10:04 AM – The TRUCKEE study real world efficacy and safety of faricimab in neovascular AMD
10:10 AM – Characteristics and outcomes of nAMD patients managed in US routine clinical practice: analysis of the IRIS registry database
10:16 AM – FARETINA studies
10:22 AM – Panel discussion

Session 3: Applied Methods
10:32 AM – I have a question, now how do I answer it? Intro to study design
10:38 AM – The importance of identifying an index date
10:44 AM – Use of RWD to augment clinical trials
10:50 AM – Considerations for using real world visual acuity in clinical outcomes research
11:38 AM – Adoption of ocular imaging standards
11:02 AM – Use of Unstructured Data in RWD Studies (Primer on NLP)
11:08 AM – Considerations for using real world images to create AI/ML algorithms
11:14 AM – Panel discussion

Session 4: Retinovascular Disease
11:24 AM – Race, Ethnicity, Sex, and Age Disparities in Initiation of Anti-Vascular Endothelial Growth Factor Therapy (VEGF) for Retinal Vein Occlusions in the AAO IRIS® Registry
11:30 AM – Treatment Patterns and 5-Year Visual Acuity Outcomes in Patients With Retinal Vein Occlusion: Analysis of a Real-World Database From the US
11:36 AM – Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes
11:42 AM – The effect of loading doses on real world DME treatment outcomes
11:48 AM – Real world outcomes of sustained steroids for DME
11:54 AM – Impact of initial monthly doses of aflibercept on visual outcomes in eyes with diabetic macular edema in routine clinical practice in the US
12:00 PM – Panel discussion

Session 5: Non-Neovascular Age related Macular Degeneration
12:10 PM – Assessment of Geographic Atrophy in an intermediate AMD population
(VEGF) for retinal vein occlusions in the AAO IRIS® registry
12:16 PM – The Under-Reporting of Geographic Atrophy
12:22 PM – Conversion rates of non-neovascular AMD to neovascular AMD
12:28 PM – Retrospective Real-World Analysis of Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration Followed for 3 Years
12:34 PM – Characterizing Real-World Functional Outcomes in Patients with Geographic Atrophy: An IRIS Registry Analysis
12:40 PM – Panel discussion
12:50 PM – Meeting adjourns